Metabolic Dysfunction-associated Steatohepatitis (MASH)

Infectious Diseases
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
1
ALN-HSDPhase 21 trial
Active Trials
NCT05519475Recruiting90Est. Sep 2027
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
No treatment givenN/A1 trial
Active Trials
NCT07201831Completed1,330Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
RegeneronALN-HSD
Novo NordiskNo treatment given

Clinical Trials (2)

Total enrollment: 1,420 patients across 2 trials

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Start: Feb 2023Est. completion: Sep 202790 patients
Phase 2Recruiting
NCT07201831Novo NordiskNo treatment given

A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population

Start: Oct 2025Est. completion: Jan 20261,330 patients
N/ACompleted

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,420 patients
2 companies competing in this space